TY - JOUR
T1 - Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer
AU - IMPACT-Metastatic Breast Consortium
AU - Boers, Jorianne
AU - Eisses, Bertha
AU - Zwager, Mieke C
AU - van Geel, Jasper J L
AU - Bensch, Frederike
AU - de Vries, Erik F J
AU - Hospers, Geke A P
AU - Glaudemans, Andor W J M
AU - Brouwers, Adrienne H
AU - den Dekker, Martijn A M
AU - Elias, Sjoerd G
AU - Kuip, Evelien J M
AU - van Herpen, Carla M L
AU - Jager, Agnes
AU - van der Veldt, Astrid A M
AU - Oprea-Lager, Daniela E
AU - de Vries, Elisabeth G E
AU - van der Vegt, Bert
AU - Menke-van der Houven van Oordt, Willemien C
AU - Schröder, Carolina P
PY - 2024/2/14
Y1 - 2024/2/14
N2 - BACKGROUND: In metastatic breast cancer (MBC), [
18F]fluorodeoxyglucose positron emission tomography/computed tomography ([
18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [
18F]FDG uptake in corresponding metastases.
PATIENTS AND METHODS: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [
18F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [
18F]FDG uptake was expressed as maximum standardized uptake value (SUV
max) and results were expressed as geometric means.
RESULTS: Of 200 patients, 188 had evaluable metastasis biopsies, and 182 of these contained tumor. HER2 positivity and Ki-67 ≥ 20% were correlated with higher [
18F]FDG uptake (estimated geometric mean SUV
max 10.0 and 8.8, respectively;
p = 0.0064 and
p = 0.014). [
18F]FDG uptake was lowest in ER-positive/HER2-negative BC and highest in HER2-positive BC (geometric mean SUV
max 6.8 and 10.0, respectively;
p = 0.0058). Although [
18F]FDG uptake was lower in invasive lobular carcinoma (
n = 31) than invasive carcinoma NST (
n = 146) (estimated geometric mean SUV
max 5.8 versus 7.8;
p = 0.014), the metastasis detection rate was similar.
CONCLUSIONS: [
18F]FDG-PET is a powerful tool to detect metastases, including invasive lobular carcinoma. Although BC histopathological characteristics are related to [
18F]FDG uptake, [
18F]FDG-PET and biopsy remain complementary in MBC staging (NCT01957332).
AB - BACKGROUND: In metastatic breast cancer (MBC), [
18F]fluorodeoxyglucose positron emission tomography/computed tomography ([
18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [
18F]FDG uptake in corresponding metastases.
PATIENTS AND METHODS: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [
18F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [
18F]FDG uptake was expressed as maximum standardized uptake value (SUV
max) and results were expressed as geometric means.
RESULTS: Of 200 patients, 188 had evaluable metastasis biopsies, and 182 of these contained tumor. HER2 positivity and Ki-67 ≥ 20% were correlated with higher [
18F]FDG uptake (estimated geometric mean SUV
max 10.0 and 8.8, respectively;
p = 0.0064 and
p = 0.014). [
18F]FDG uptake was lowest in ER-positive/HER2-negative BC and highest in HER2-positive BC (geometric mean SUV
max 6.8 and 10.0, respectively;
p = 0.0058). Although [
18F]FDG uptake was lower in invasive lobular carcinoma (
n = 31) than invasive carcinoma NST (
n = 146) (estimated geometric mean SUV
max 5.8 versus 7.8;
p = 0.014), the metastasis detection rate was similar.
CONCLUSIONS: [
18F]FDG-PET is a powerful tool to detect metastases, including invasive lobular carcinoma. Although BC histopathological characteristics are related to [
18F]FDG uptake, [
18F]FDG-PET and biopsy remain complementary in MBC staging (NCT01957332).
KW - [18F]FDG-PET
KW - breast cancer
KW - metastases
KW - histopathological characteristics
U2 - 10.3390/diagnostics14040416
DO - 10.3390/diagnostics14040416
M3 - Article
C2 - 38396455
SN - 2075-4418
VL - 14
JO - Diagnostics
JF - Diagnostics
IS - 4
M1 - 416
ER -